- Home
- PKX vs RPRX Comparison
PKX vs RPRX Comparison
Compare PKX & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PKX | RPRX |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.4B | 16.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PKX | RPRX |
|---|---|---|
| Price | $53.08 | $39.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $46.00 |
| AVG Volume (30 Days) | 154.0K | ★ 4.3M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | 1.99% | ★ 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.27 | 1.75 |
| Revenue | ★ $49,870,827,432.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.13 |
| Revenue Next Year | $4.11 | $1.48 |
| P/E Ratio | $49.09 | ★ $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $39.40 | $24.05 |
| 52 Week High | $61.24 | $41.24 |
Technical Indicators
Market Signals| Indicator | PKX | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 57.50 |
| Support Level | $52.00 | $39.24 |
| Resistance Level | $53.63 | $40.50 |
| Average True Range (ATR) | 1.01 | 0.91 |
| MACD | -0.17 | -0.08 |
| Stochastic Oscillator | 37.25 | 76.02 |
Price Performance
Historical ComparisonAbout PKX POSCO Holdings Inc.
POSCO Holdings Inc is a holding company and operates through its subsidiaries. The company operates across four distinct segments. The first segment is the Steel Segment, which includes the production and sale of steel products. The second segment is the Infrastructure Business, which is further divided into three operations. The Trading Segment comprises trading and natural resource development activities. The Construction Segment involves the planning, designing, and construction of industrial plants, civil engineering projects, and buildings. The Logistics and Others Segment. The third segment is the Secondary Battery Materials Segment, and the fourth segment is the Others Segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.